Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 747 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Accelrys unveils modeling and simulation software

The solution enhances Discovery Studio’s portfolio of small-molecule ligand design and market-leading biological simulation tools. The software works on a spatial aggregation propensity algorithm and Developability Index issued

PSE releases gCRYSTAL software

The software has been developed in collaboration with several companies from different industries where crystallisation processes,including precipitation plays a key role. The technology provides an integrated, easy-to-use, drag

InterMune completes sale of Actimmune

Gross proceeds from the sale totaled $55m, while InterMune is eligible to gain a two-year royalty stream based on net sales of Actimmune. InterMune chairman, chief executive officer

AstraZeneca takes over Ardea Biosciences

Upon completion of the merger, approved by Ardea’s stockholders, each outstanding share of Ardea common stock has been cancelled and converted into the right to receive $32.00, in

Lubrizol to take over Lipotec

Under the agreement, Lipotec will take over cosmetic active ingredients business and its subsidiaries, Diverdrugs and Lipofoods. The transaction, which is expected to close within 60 days and

DSM enters XD Technology services agreement

XD technology is a cell culture process with achievement of 5-to-15 times higher in comparison to current standard bio manufacturing processes. It is widely applicable for multiple products